Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2012-11-09 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2012, by Galectin Therapeutics Inc. It specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that a press release containing financial information for the three and nine months ended September 30, 2012, is furnished as Exhibit 99.1. The document itself is a short current report announcing the release of financial results, not the full financial report or earnings release itself. The text indicates the press release is "being furnished and not filed herewith," which is typical for an 8-K filing that announces or provides a summary of financial results. Given the short length (2270 characters) and the nature of the content, this is an announcement of financial results rather than the full earnings release or interim report. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain substantive financial data or the full report itself.
2012-11-09 English
FORM 10-Q
Interim / Quarterly Report Q3 2012
2012-11-09 English
PRIMARY DOCUMENT
Director's Dealing
2012-10-15 English
PRIMARY DOCUMENT
Director's Dealing
2012-10-10 English
PRIMARY DOCUMENT
Director's Dealing
2012-10-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement due to a breach, which is a significant corporate event. It does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual report. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material event, fitting the category of Regulatory Filings (RNS). The document length is short (2531 characters), and it is a standalone announcement of a corporate event, not a full report or presentation.
2012-10-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.